TrialRheumatology (Oxford, England)2023

A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.

Ariane L Herrick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.